ICCM — IceCure Medical Ltd.

Is ICCM overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Oversold As of October 3, 2026

IceCure Medical Ltd. (ICCM) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Medical Devices) last closed at $1.57. The rating moved from Strong Oversold to Oversold on October 2, 2026.

See all oversold Healthcare stocks →

AI analysis

IceCure Medical Ltd. (ICCM) is a small-cap medical device company focused on cryoablation procedures with a concentrated set of clinical and commercial levers. The company’s near-term outlook depends heavily on adoption trends, reimbursement outcomes, and access to capital. Market conditions are presently risk-averse for healthcare/device issuances, which increases funding and sentiment headwinds. Potential upside exists from positive clinical readouts, regulatory milestones, or partnership deals, but those are offset by execution, payer and dilution risks. Given limited public financial detail in the provided inputs, the stock should be monitored for financing developments, sales traction, and any new clinical/regulatory catalysts before adjusting positioning.

Key factors

  • Niche cryoablation technology with addressable opportunity in benign and malignant tumor treatments
  • Small-cap profile with limited liquidity increases volatility and widens bid/ask; market moves sensitive to headlines and funding news
  • Adoption and reimbursement dynamics are central — clinical outcomes and physician acceptance drive procedure uptake
  • Macro risk-off environment for device/consumer-health deals is suppressing investor appetite for new offerings and secondary raises
  • Potential catalysts include new clinical data, regulatory clearances or expanded payer coverage and strategic partnerships or distribution deals
  • Limited recent public financial detail in the provided dataset increases uncertainty about cash runway and near-term financing needs

Risks

  • Cash runway and need for additional financing which could lead to dilution
  • Slow commercial adoption and insufficient reimbursement rates limiting revenue scale
  • Clinical or regulatory setbacks that delay approvals or restrict market access
  • Intense competition from alternative ablation modalities and emerging technologies
  • Small-cap liquidity risk and heightened sensitivity to macro risk-off sentiment
  • Geopolitical or macro developments that pressure investor risk appetite and medical device funding

See today's live rating, score and targets

Members see the live hourly rating for ICCM — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.